Presentations & Media

ARVO Presentation, 2016

“Potential Beneficial Effect of Low Dose Danazol in Combination With Renin Angiotensin System Inhibitors in Diabetic Macular Edema: a 12-week Double Blind Randomized Controlled Trial.” Program number 3150; Poster Board number C0050

ARVO Poster V2

Abstract, ARVO Abstract, 2016


WOC Presentation, 2016

“Potential Beneficial Effect of Low Dose Danazol in Combination With Renin Angiotensin System Inhibitors in Diabetic Macular Edema: a 12-week Multicenter Double-Blind Randomized Controlled Trial.”

http://woc.conference2web.com/content/4563?from_view=all&view_address=search%3DDanazol


Informational Videos from our Management Team

These Interviews were conducted as of September 2015 and the statements made in these videos are based upon the facts and beliefs of Ampio’s Management team on the date the interviews were conducted. There were forward looking statements contained in these interviews as of that date. Please see Ampio’s forward looking statement below.

Roundtable
Promises and Risks of Lead Drug Ampion

Michael Macaluso, CEO 
Why I Invested In Ampio and Became CEO

Dr. Vaughan Clift, MD 
Ampion To Treat Osteoarthritis of the Knee and Other Joints

Dr. Vaughan Clift, MD 
Ampion Pivotal Phase III Trial Underway

Dr. Vaughan Clift, MD 
Pathway To Ampion Commercialization

Dr. David Bar-Or, MD
Ampion To Treat and Regenerate Broad Indications Beyond Osteoarthritis

Dr. Vaughan Clift, MD
Optina To Treat Diabetic Macular Edema and Beyond

Dr. David Bar-Or, MD
Scientific Presentation

Forward Looking Statements
Ampio’s statements in these videos are based upon the facts and beliefs of Ampio’s Management team as of the date the interviews were conducted. Statements as of September 2015 that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to the Ampion™ PIVOT trial, other Ampion trials, the Optina trials as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. These forward-looking statements also include statements regarding the Special Protocol Assessment (SPA) as well as the classification of Ampion™ as a novel biologic with 12 years exclusivity. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.